Release Date: February 13, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you discuss the benchmarks for the upcoming obesity data and what would be considered a win for your study regarding weight loss at 8 weeks? A: Carl Spana, President and CEO, explained that the study is a signal detection study without a preconceived number. They are looking for a clear signal, such as a higher percentage of weight loss in the combined arm and key metrics like the percentage of patients achieving significant weight loss. The study aims to see if the co-administration can reverse the slowdown in weight loss seen with Tirzepatide monotherapy. They are also interested in whether Bremelanotide alone can blunt weight regain, indicating weight loss maintenance.
Q: Are there additional indications you might consider beyond the broader weight loss community, such as orphan indications for MCR-4? A: Carl Spana mentioned that there is a growing opportunity for using melanocortin-4 receptor agonists in rare and orphan syndromic diseases, such as Prader Willi syndrome and Barde Bartle. Hypothalamic obesity is a significant market opportunity, and their new compounds are expected to be competitive in this space. They are likely to focus on the rare space for these indications.
Q: What are the key concepts you are looking for in the obesity study? A: Carl Spana stated that they are looking for an increase in absolute weight loss on a percentage basis, without a specific magical number. The study is not optimized for a big jump but aims to get a clear signal. They are also interested in the Bremelanotide alone arm versus the placebo arm to see if it can blunt weight regain, supporting the concept of weight loss maintenance.
Q: How does the investment community's viewpoint affect your study's benchmarks? A: Joseph Pantginis noted that the investment community might compare the study against benchmarks, which could drive expectations for a win from a percentage standpoint. Carl Spana acknowledged this but emphasized their approach of looking for a clear signal rather than focusing on specific benchmarks.
Q: What is the significance of the upcoming data for Palatin Technologies? A: Carl Spana expressed excitement about the upcoming data and the potential impact on their strategy. The results will be crucial for their focus on Melanocortin-4 Receptor obesity assets, which they believe will play a significant role in the future of obesity treatment and weight loss management.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.